D.ZlokovicB
Data that remained non-normally distributed and/or heteroscedastic after log transformation were analyzed (not log-transformed, but still 1e13-transformed) with a KruskalWallis test, while normally distributed and homoscedastic data were analyzed with a one-way ANOVA, performed on the log-transformed data as necessary
However, experts have expressed concern that there is little scientific evidence to support the peptides being considered
It is important to note that whilst the injection itself may maintain adequate B12 levels for weeks to months, the clinical benefits such as improved energy, cognitive function, and resolution of neurological symptomsdepend on consistent maintenance of optimal levels
Face: The most responsive area, with the strongest clinical evidence
SS-31 (Elamipretide): The First FDA-Approved Mitochondrial Therapeutic In September 2025, the FDA granted accelerated approval to Forzinity (elamipretide), marking a watershed moment in mitochondrial medicine